Comorbidities and Management Strategies in Heart Failure
Summary
Heart failure (HF) represents a growing global challenge, not only as a primary cardiac disorder but also through its frequent coexistence with multiple comorbid conditions. Cardiometabolic diseases such as diabetes and chronic kidney disease, pulmonary disorders including chronic obstructive pulmonary disease, and non-cardiovascular issues such as anaemia, depression and frailty each compound symptom burden, impair functional capacity and worsen prognosis. Phenotypic distinctions between heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) further shape the comorbidity profile and therapeutic response. Management strategies have evolved from a narrow focus on guideline-directed medical therapy to integrated care pathways incorporating aggressive risk factor control, tailored pharmacotherapy, structured polypharmacy review and multidisciplinary clinics. Advances in diagnostic imaging, biomarker assessment and health-status instruments have refined risk stratification, allowing personalised, comorbidity-guided treatment plans. Telemonitoring and remote-care models are under evaluation to pre-empt decompensation, optimise medication adherence and reduce admissions. Despite technical progress, real-world implementation of comprehensive management remains uneven, and the interplay between comorbid burden, treatment complexity and patient quality of life remains a priority for future research.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Comorbidities and Management Strategies in Heart Failure publication trend
The graph below shows the total number of articles in comorbidities and management strategies in heart failure across all publications each year (not limited to Nature Index journals).
Technical terms
Comorbidity: The presence of one or more additional medical conditions coexisting with a primary disease, here referring to non-cardiac and cardiac conditions alongside heart failure.
Ejection fraction (EF): The proportion of blood ejected from the left ventricle with each contraction, used to categorise heart failure phenotypes (reduced vs preserved).
Heart failure with reduced ejection fraction (HFrEF): A form of heart failure characterised by an EF below normal thresholds, typically <40%, indicating impaired systolic function.
Heart failure with preserved ejection fraction (HFpEF): Heart failure in which EF is ≥50%, often associated with diastolic dysfunction and high comorbidity burden.
Polypharmacy: The concurrent use of multiple medications by a patient, often defined as five or more drugs, which may be therapeutic or pose increased risk of adverse outcomes.
References
- Heart Failure with Preserved Ejection Fraction and Cardiac Amyloidosis in the Aging Heart. International Journal of Molecular Sciences (2024).
- Impact of polypharmacy phenogroups on different heart failure phenotypes in patients with chronic heart failure: a retrospective examination of real-world cohort. Frontiers in Pharmacology (2025).
- Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. European Journal of Heart Failure (2023).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.